{
    "clinical_study": {
        "@rank": "6690", 
        "acronym": "ELOUAN", 
        "arm_group": [
            {
                "arm_group_label": "induction phase + intravitreal inj.", 
                "description": "Group of patients who received Lucentis \u00ae  with induction phase"
            }, 
            {
                "arm_group_label": "intravitreal inj. without induction", 
                "description": "Group of patients who received Lucentis \u00ae  without induction phase"
            }, 
            {
                "arm_group_label": "intravitreal inj. + monthly  follow-up", 
                "description": "group of patients who were monthly monitored (+/- 1 week)"
            }, 
            {
                "arm_group_label": "intravitreal inj. + follow-up :> 1 month", 
                "description": "group of patients with Follow up visits intervals> 1 month (+/- 1 week)"
            }, 
            {
                "arm_group_label": "intravitreal inj +induction+ month. FU", 
                "description": "Group of patients who received Lucentis with induction phase and who were monthly monitored (+/- 1 week)"
            }, 
            {
                "arm_group_label": "date Lucentis\u00ae 1st intravitreal Inj.", 
                "description": "Group of patients selected in accordance with the date of Lucentis\u00ae  treatment start."
            }
        ], 
        "brief_summary": {
            "textblock": "Main Objective: The main objective of this retrospective observational study was to describe\n      the evolution of visual acuity measured on ETDRS (Early Treatment Diabetic Retinopathy\n      Study) scale, for patients with exudative Age-Related Macular Degeneration (ARMD),  treated\n      with Lucentis, under real conditions of care, in terms of mean change of the Best Corrected\n      Visual Acuity (BCVA), measured at 24 months (\u00b1 4 weeks)."
        }, 
        "brief_title": "Monocentric Retrospective Observational Study on Patients With Macular Degeneration", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Exudative Age-Related Macular Degeneration", 
        "condition_browse": {
            "mesh_term": [
                "Macular Degeneration", 
                "Wet Macular Degeneration"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with exudative-subfove ARMD, regardless the neovessel type or the initial\n             visual acuity; 2 - Patients treated in the department with intra vitreous injection\n             of Lucentis \u00ae during the study period (08/2011 and 02/2013); 3 - If both eyes are\n             eligible, both will be analyzed;\n\n        Exclusion Criteria:\n\n          1. - Patients who received, for the studied eye, a  treatment with a Vascular\n             endothelial growth factor (VEGF) other than Lucentis \u00ae in the three months preceding\n             the start of the study. For those who received combination therapy, the nature of the\n             treatment will be specified and taken into account in the subgroups for statistical\n             analyzes;\n\n          2. - Patients with high myopia or neovessel not related to exudative-ARMD;"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "patients with exudative Age-Related Macular Degeneration (ARMD),  treated with Lucentis,\n        under real conditions of care"
            }
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02089503", 
            "org_study_id": "ELOUAN HSJ 2014"
        }, 
        "intervention": {
            "arm_group_label": [
                "induction phase + intravitreal inj.", 
                "intravitreal inj. without induction", 
                "intravitreal inj. + monthly  follow-up", 
                "intravitreal inj. + follow-up :> 1 month", 
                "intravitreal inj +induction+ month. FU", 
                "date Lucentis\u00ae 1st intravitreal Inj."
            ], 
            "description": "intravitreal injections FOR ALL PATIENTS of Lucentis as required in the normal condition of use", 
            "intervention_name": "intravitreal injections of Lucentis", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 17, 2014", 
        "location": {
            "contact": {
                "last_name": "Frederic QUEGUINER, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Marseille", 
                    "country": "France", 
                    "zip": "13008"
                }, 
                "name": "Hopital Saint Joseph"
            }, 
            "investigator": {
                "last_name": "Frederic QUEGUINER, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "6", 
        "official_title": "Monocentric Retrospective Observational Study Describing the Visual Acuity of Patients With Exudative Age Related Macular Degeneration and Treated by Lucentis\u00ae Under Real Conditions of Care.", 
        "overall_contact": {
            "email": "fqueguiner@hopital-saint-joseph.fr", 
            "last_name": "Frederic QUEGUINER, MD", 
            "phone": "+33491806793"
        }, 
        "overall_official": {
            "affiliation": "HSJ", 
            "last_name": "Maud RIGHINI, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: Committee for the Protection of Personnes", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Best Corrected Visual Acuity (BCVA), measured at 24 months (\u00b1 4 weeks).", 
            "safety_issue": "Yes", 
            "time_frame": "measured at 24 months (\u00b1 4 weeks)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02089503"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hospital St. Joseph, Marseille, France", 
            "investigator_full_name": "QUEGUINER, MD", 
            "investigator_title": "Ophtalmologist", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "the mean change of the BCVA throughout the 24 months of follow-up (FU),", 
            "safety_issue": "Yes", 
            "time_frame": "24 months of follow-up"
        }, 
        "source": "Hospital St. Joseph, Marseille, France", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hospital St. Joseph, Marseille, France", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}